Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fast MRI finds cancers mammograms miss in breast cancer survivors

NCT ID NCT03664778

Diagnosis Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a fast (abbreviated) breast MRI can detect cancers that mammograms miss in women who have already been treated for breast cancer with lumpectomy and radiation. Researchers recruited 184 women who had a normal 3D mammogram and gave them a quick MRI. The goal was to see if the MRI could find small, hidden cancers in the breast or nearby lymph nodes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
abbreviated (fast) breast MRI
What this could lead to
If successful, this could show that a fast MRI is a useful extra screening tool to catch cancers that mammograms miss in women who have had breast-conserving therapy.
What could go wrong
This is a small, single-center study with only 184 participants, so results may not apply to all women. The fast MRI may also find false alarms that lead to unnecessary biopsies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

184 people

The number who actually took part.

Started

Sep 2018

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women who have had primary breast cancer treated with breast conservation therapy and who fit the inclusion criteria listed below.

Ages

18 to 82 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Status post primary breast cancer (both invasive and DCIS) treated with breast conservation therapy at least three years prior to recruitment 2. Negative DBT examination within six months prior to recruitment 3. All breast densities 4. Clinically asymptomatic - no palpable masses or focal thickening, etc. Exclusion Criteria: 1. Patients who are pregnant or lactating. 2. Patients who have not had a mammogram (digital breast tomosynthesis) in the past 6 months. 3. Patients who are unwilling or unable to provide written informed consent. 4. Patients symptomatic for breast disease (e.g. experiencing discharge, lumps, etc.). 5. Recent breast surgery in the past two years including breast enhancements (e.g. implants or injections) benign surgical biopsies. 6. Patients who are unable to receive an MRI with Gadolinium contrast. 7. Patients who have not had an MRI of the breast within the past year.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm ductal breast carcinoma in situ

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasms Carcinoma, intraductal, noninfiltrating

Contacts and locations

Locations

  • UPenn

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.